Want to see IN:ALEMBICLTD full AI Analyst Report?
ALEMBICLTD Stock Chart & Stats
₹103.40
-₹1.48(-1.12%)
At close: 4:00 PM EST
₹103.40
-₹1.48(-1.12%)
Day’s Range― - ―
52-Week Range₹70.64 - ₹108.55
Previous CloseN/A
Volume165.88K
Average Volume (3M)22.23K
Market Cap
₹25.72B
Enterprise Value₹17.32K
Total Cash (Recent Filing)₹980.38M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)7.9
Beta1.30
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.43%
Share Statistics
EPS (TTM)12.48
Shares Outstanding256,781,830
10 Day Avg. Volume15,327
30 Day Avg. Volume22,227
Financial Highlights & Ratios
PEG Ratio2.67
Price to Book (P/B)0.74
Price to Sales (P/S)7.59
P/FCF Ratio17.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthThe multi-year increase in revenue indicates expanding product demand and commercial reach. Continued top-line growth provides a durable foundation for the pharmaceutical portfolio, although future benefits depend on maintaining operating profitability.
Very Low Financial LeverageMinimal debt materially reduces solvency and refinancing risk while preserving financial flexibility. A conservatively financed balance sheet can help Alembic fund manufacturing, product development, and market expansion through weaker industry conditions.
Improving Cash GenerationThe sharp improvement in operating and free cash flow strengthens internal funding capacity and supports reinvestment without relying heavily on debt. If sustained, better cash conversion would improve the durability of reported earnings and capital allocation.
Bears Say
Operating Profitability DeclineThe decline in EBITDA and EBIT shows that recent revenue growth has not translated consistently into operating earnings. Persistent margin pressure could constrain reinvestment, weaken returns, and reduce the quality of future growth across products and markets.
Earnings Quality UncertaintyA sustained mismatch between net income and revenue makes reported profitability harder to assess and raises dependence on non-operating items. This uncertainty can limit confidence in earnings durability until operating results become a clearer driver of profits.
Historically Volatile Cash ConversionPrior periods of weak or negative operating cash flow indicate working-capital, collection, or earnings-conversion risks. Although 2026 improved materially, inconsistent cash generation remains a structural concern for funding operations and shareholder returns.
Alembic Limited News
ALEMBICLTD FAQ
What was Alembic Limited’s price range in the past 12 months?
Alembic Limited lowest stock price was ₹70.64 and its highest was ₹108.55 in the past 12 months.
What is Alembic Limited’s market cap?
Alembic Limited’s market cap is ₹25.72B.
When is Alembic Limited’s upcoming earnings report date?
Alembic Limited’s upcoming earnings report date is Nov 06, 2026 which is in 66 days.
How were Alembic Limited’s earnings last quarter?
Alembic Limited released its earnings results on Aug 11, 2026. The company reported ₹2.527 earnings per share for the quarter.
Is Alembic Limited overvalued?
According to Wall Street analysts Alembic Limited’s price is currently Overvalued.
Does Alembic Limited pay dividends?
Alembic Limited pays a Annually dividend of ₹2.4 which represents an annual dividend yield of 2.43%. See more information on Alembic Limited dividends here
What is Alembic Limited’s EPS estimate?
Alembic Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alembic Limited have?
Alembic Limited has 256,781,830 shares outstanding.
What happened to Alembic Limited’s price movement after its last earnings report?
Alembic Limited reported an EPS of ₹2.527 in its last earnings report. Following the earnings report the stock price went up 2.432%.
Which hedge fund is a major shareholder of Alembic Limited?
Currently, no hedge funds are holding shares in IN:ALEMBICLTD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alembic Limited
Alembic Limited primarily manufactures and globally distributes active pharmaceutical ingredients (APIs) developed through both fermentation and chemical synthesis. The company operates across two distinct divisions: API and Real Estate. In its real estate ventures, Alembic undertakes the construction of residential and commercial properties, offers project management and marketing consultancy services, and leases commercial spaces. Furthermore, it operates its own power generation facilities, including co-generation plants with a total capacity of 11 MW and wind power plants contributing 5 MW. Founded in 1907 and headquartered in Vadodara, India, Alembic Limited is a subsidiary of Nirayu Limited.
Technical Analysis
Ajmera Realty & Infra India Ltd
―
Arkade Developers Limited
―
Arvind SmartSpaces Ltd.
―
Hubtown Limited
―
Marathon Nextgen Realty Limited
―

